Atopic Dermatitis Industry to show steady growth, H2 2017

Overview

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/1773620-atopic-dermatitis-pipeline-review-h2-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 40, 20, 1, 47, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 2 molecules, respectively.

 Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology). 
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects. 
Table of Contents 

Table of Contents 2 
Introduction 6 
Atopic Dermatitis - Overview 7 
Atopic Dermatitis - Therapeutics Development 8 
Atopic Dermatitis - Therapeutics Assessment 25 
Atopic Dermatitis - Companies Involved in Therapeutics Development 37 
Atopic Dermatitis - Drug Profiles 76 
Atopic Dermatitis - Dormant Projects 350 
Atopic Dermatitis - Discontinued Products 356 
Atopic Dermatitis - Product Development Milestones 357 
Appendix 367

List of Tables 
Number of Products under Development for Atopic Dermatitis, H2 2017 
Number of Products under Development by Companies, H2 2017 
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 

  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1773620-atopic-dermatitis-pipeline-review-h2-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.